Halozyme Therapeutics (HALO) Proxy filing summary

Executive summary

• The 2026 Annual Meeting will be held virtually on May 5, 2026, with voting available online, by phone, or mail.

• Stockholders will vote on electing two Class I directors, an advisory say-on-pay vote, and ratification of the external auditor.

• The Board recommends voting FOR all proposals and nominees.

• 2025 saw record revenues ($1.397B, up 38%), strong stockholder returns (stock up 40% in 2025), and significant business milestones including acquisitions and new licensing agreements.

Voting matters and shareholder proposals

• Proposals include: (1) election of two Class I directors for three-year terms, (2) advisory vote on executive compensation, (3) ratification of Ernst & Young LLP as auditor.

• Board recommends FOR all proposals.

• Shareholders may submit proposals for the 2027 meeting by November 23, 2026.

Board of directors and corporate governance

• Board is classified into three classes with staggered terms; two Class I directors up for election in 2026.

• Board emphasizes diversity in skills, experience, gender, and race.

• All directors except the CEO are independent; Board Chair is independent.

• Three standing committees: Audit, Compensation, and Nominating & Corporate Governance.

• Directors attend at least 75% of meetings; executive sessions held without management.